ATE257385T1 - Zusammensetzungen und verfahren zur behandlung des erhöhten augenindruckes - Google Patents

Zusammensetzungen und verfahren zur behandlung des erhöhten augenindruckes

Info

Publication number
ATE257385T1
ATE257385T1 AT98916948T AT98916948T ATE257385T1 AT E257385 T1 ATE257385 T1 AT E257385T1 AT 98916948 T AT98916948 T AT 98916948T AT 98916948 T AT98916948 T AT 98916948T AT E257385 T1 ATE257385 T1 AT E257385T1
Authority
AT
Austria
Prior art keywords
compositions
methods
eye pressure
increased eye
treating increased
Prior art date
Application number
AT98916948T
Other languages
English (en)
Inventor
Kenneth Warren Reed
Shau-Fong Yen
Mary Sou
Regina Flinn Peacock
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE257385(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE257385T1 publication Critical patent/ATE257385T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98916948T 1997-03-17 1998-03-13 Zusammensetzungen und verfahren zur behandlung des erhöhten augenindruckes ATE257385T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17
PCT/EP1998/001483 WO1998041208A1 (en) 1997-03-17 1998-03-13 Compositions and methods for reducing ocular hypertension

Publications (1)

Publication Number Publication Date
ATE257385T1 true ATE257385T1 (de) 2004-01-15

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98916948T ATE257385T1 (de) 1997-03-17 1998-03-13 Zusammensetzungen und verfahren zur behandlung des erhöhten augenindruckes

Country Status (32)

Country Link
EP (1) EP0969846B2 (de)
JP (2) JP4920124B2 (de)
KR (1) KR100555818B1 (de)
CN (1) CN1236775C (de)
AR (2) AR002194A1 (de)
AT (1) ATE257385T1 (de)
AU (1) AU738781B2 (de)
BR (2) BR9808016A (de)
CA (1) CA2280089C (de)
CL (1) CL2009001870A1 (de)
CO (1) CO4940427A1 (de)
CY (1) CY2526B1 (de)
CZ (1) CZ299833B6 (de)
DE (1) DE69820997T3 (de)
DK (1) DK0969846T4 (de)
EE (1) EE04091B1 (de)
ES (1) ES2214706T5 (de)
HU (1) HU228896B1 (de)
ID (1) ID22389A (de)
IL (1) IL131041A0 (de)
MY (1) MY122237A (de)
NO (1) NO327713B1 (de)
NZ (1) NZ337322A (de)
PE (1) PE61899A1 (de)
PL (1) PL197509B1 (de)
PT (1) PT969846E (de)
RU (1) RU2197970C2 (de)
SI (1) SI0969846T2 (de)
TW (1) TW527187B (de)
UA (1) UA63938C2 (de)
WO (1) WO1998041208A1 (de)
ZA (1) ZA982188B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) * 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
CA2422031C (en) * 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
WO2002045748A1 (en) * 2000-12-05 2002-06-13 Sankyo Company, Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
RU2266572C1 (ru) * 2004-03-17 2005-12-20 Российский государственный медицинский университет Способ моделирования злокачественной артериальной гипертонии
US20070208068A1 (en) * 2004-03-18 2007-09-06 R-Tech Ueno, Ltd. & Astellas Pharma Inc. Aqueous Composition Comprising Thiazole Derivative
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
DE202005005094U1 (de) * 2005-03-31 2005-07-28 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Ophthalmische Zusammensetzung
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
US8030349B2 (en) * 2005-08-02 2011-10-04 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable medicament
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
CA2645311C (en) * 2006-03-13 2014-11-18 R-Tech Ueno, Ltd. Aqueous composition comprising 15-keto-prostaglandin for ophthalmic use
AR059927A1 (es) * 2006-03-17 2008-05-07 Johnson & Johnson Vision Care Metodos para la estabilizacion de composiciones inestables a la oxidacion y composiciones oftalmicas estabilizadas
ZA200902453B (en) * 2006-10-31 2010-07-28 Alcon Res Ltd PAI-1 binding modulators for the treatment of ocular disorders
US20100120908A1 (en) * 2007-02-07 2010-05-13 Teika Pharmaceutical Co., Ltd Eye drop preparation comprising latanoprost
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
BRPI0819081A8 (pt) * 2007-10-08 2016-08-30 Fovea Pharmaceuticals Sa Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento
CN101959500A (zh) * 2008-03-17 2011-01-26 爱尔康研究有限公司 包含硼酸类化合物-多元醇络合物的水性药物组合物
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (de) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
RU2402316C2 (ru) * 2009-01-11 2010-10-27 Пшеничников Виталий Георгиевич Фармацевтическая антиглаукомная композиция
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
KR20140038404A (ko) * 2011-04-12 2014-03-28 가부시키가이샤 아루떼꾸 우에노 수성 안과용 조성물
US20130029919A1 (en) * 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (de) 2011-09-12 2013-03-13 Visiotact Pharma Ophthalmische Zusammensetzungen enhaltend Prostaglandin-F2-alpha-Derivate und Hyaluronsäure
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
EP2787969B1 (de) 2011-12-07 2021-09-29 Allergan, Inc. Effiziente lipidabgabe an den menschlichen tränenfilm unter verwendung eines salzempfindlichen emulsionssystems
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
EP3223794A1 (de) 2014-11-25 2017-10-04 Allergan, Inc. Stabilisierte ophthalmische omega-3-zusammensetzungen
WO2020061550A1 (en) * 2018-09-21 2020-03-26 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
MX2021012399A (es) 2019-04-12 2021-12-10 Ecolab Usa Inc Limpiador antimicrobiano multiuso y métodos de fabricación y uso de este.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059058T3 (es) * 1990-05-22 1994-11-01 R Tech Ueno Ltd Combinacion sinergica para uso oftalmico.
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
WO1992013836A1 (en) * 1991-02-07 1992-08-20 Allergan, Inc. 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f derivatives
CA2166722A1 (en) * 1994-05-06 1995-11-16 Manoj L. Maniar Use of vitamin e tocopheryl derivatives in ophthalmic compositions
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
PL197509B1 (pl) 2008-04-30
DE69820997D1 (de) 2004-02-12
CZ299833B6 (cs) 2008-12-10
JP2010043110A (ja) 2010-02-25
EE9900410A (et) 2000-04-17
SI0969846T2 (sl) 2010-12-31
KR20000076330A (ko) 2000-12-26
RU2197970C2 (ru) 2003-02-10
CN1236775C (zh) 2006-01-18
DK0969846T4 (da) 2010-12-20
NO994481L (no) 1999-09-16
SI0969846T1 (en) 2004-06-30
CN1249687A (zh) 2000-04-05
PT969846E (pt) 2004-05-31
PL335168A1 (en) 2000-04-10
MY122237A (en) 2006-04-29
CO4940427A1 (es) 2000-07-24
CL2009001870A1 (es) 2010-01-22
DE69820997T2 (de) 2004-12-09
EE04091B1 (et) 2003-08-15
CY2526B1 (en) 2006-02-08
CA2280089C (en) 2009-03-03
EP0969846A1 (de) 2000-01-12
AR011192A1 (es) 2000-08-02
PE61899A1 (es) 1999-06-30
BR9808016A (pt) 2000-03-08
IL131041A0 (en) 2001-01-28
DE69820997T3 (de) 2011-10-06
HU228896B1 (en) 2013-06-28
CZ325799A3 (cs) 2000-01-12
BRPI9816218B1 (pt) 2016-04-12
AU7035398A (en) 1998-10-12
EP0969846B2 (de) 2010-08-25
JP4920124B2 (ja) 2012-04-18
AU738781B2 (en) 2001-09-27
CA2280089A1 (en) 1998-09-24
NO327713B1 (no) 2009-09-14
DK0969846T3 (da) 2004-04-13
NO994481D0 (no) 1999-09-16
ES2214706T5 (es) 2011-02-02
TW527187B (en) 2003-04-11
NZ337322A (en) 2001-05-25
JP2001515502A (ja) 2001-09-18
HK1026841A1 (en) 2000-12-29
ID22389A (id) 1999-10-07
KR100555818B1 (ko) 2006-03-03
ZA982188B (en) 1998-09-17
EP0969846B1 (de) 2004-01-07
HUP0002194A2 (hu) 2000-12-28
HUP0002194A3 (en) 2012-08-28
UA63938C2 (uk) 2004-02-16
WO1998041208A1 (en) 1998-09-24
ES2214706T3 (es) 2004-09-16
AR002194A1 (es) 1998-01-07

Similar Documents

Publication Publication Date Title
DE69820997D1 (de) Zusammensetzungen und verfahren zur behandlung des erhöhten augenindruckes
DE69942680D1 (de) Verfahren und Zusammensetzungen zur Prävention und Behandlung von Anämie
DE69807538D1 (de) Vorrichtung und Verfahren zur Behandlung von Gewebe
ATE230606T1 (de) Verfahren zur vorbeugung und behandlung von allergien
DE69925266D1 (de) Verfahren und gerät zur behandlung von herzarhythmie
DE69726289D1 (de) Verfahren und zusammensetzung zur behandlung von substraten bezüglich benetzbarkeit
DE69839261D1 (de) Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen
DE69829336D1 (de) Vorrichtung und Verfahren zur Behandlung von Körpergewebe
DE69732152D1 (de) Vorrichtung zur Behandlung von Kopfschmerzen
DE69806970D1 (de) Verfahren zur behandlung von hartgeweben
DE69829625D1 (de) Verfahren und Vorrichtung zur Behandlung von Perfluorokohlenstoff
DE69517512D1 (de) Neue zusammensetzungen und verfahren zur wasseraufbereitung
DE69534416D1 (de) Verfahren und formulierungen zur bekämpfung von schadinsekten
DE69602847D1 (de) Tuberkilizide synergistische desinfizierende zusammensetzung und verfahren zur desinfektion
DE69800072D1 (de) Vorrichtung zur Behandlung und/oder zum Schmincken von Keratinfasern
ATE415163T1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
EP1109548A4 (de) Zusammensetzungen und verfahren zur behandlung und vorbeugung von knochenkrankheiten unter verwendung von tocotrienole
DE69626311D1 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
EP0883674A4 (de) Desinfizierende zusammensetzungen und verfahren zur desinfektion von oberflachen
ATE224652T1 (de) Verfahren und einrichtung zur behandlung von tabak
DE69900339D1 (de) Mittel und Verfahren zur Behandlung von Kunstfasern
DE69936994D1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
DE69935858D1 (de) Verfahren und vorrichtung zur behandlung von scheiben
ATE307871T1 (de) Verfahren zur behandlung von gewebe
DE10083662T1 (de) Verfahren zur Behandlung von Kohlenasche und Verfahren zur Entschwefelung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0969846

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 0969846

Country of ref document: EP